Skip to main content

Table 13 Other conditions

From: Benefits and harms of medical cannabis: a scoping review of systematic reviews

Author, year {refid}

Search dates; # databases searched

Funding source

Nstudies

Illness/condition

Intervention/comparator*

Outcomes

Conclusions from data

AMSTAR-2 rating

Huntley, 2000 [66]

Inception to Dec 1999; 4

NR

1

Asthma

I: Plant-derived cannabinoids

C: Placebo

• Airway resistance (raw)

Only one study included

M

Singh, 2007 [77]

Inception to Dec 2004; 6

Non-profit

4

Asthma

I: Plant-based cannabis

C: Placebo; isoproterenol; low-dose marijuana

• Pulmonary function test

Reported SBS

M

Snedecor, 2013 [70]

To Jun 2011; 5

Industry

1

Diabetes

I: Plant-derived cannabinoids

C: placebo

• Peripheral NP (mean reduction in pain)

• Peripheral NP (mean probability of 30% pain reduction)

Unclear efficacy (not enough information provided by authors)

L

Norton, 2017 [28]

Inception–Feb 2016; 5

NR

3

Inflammatory bowel disease

I: Plant-based cannabis

C: No comparator (observational study)

N/A observational data

N/A observational data

CL

Langhorst, 2015 [44]

Inception–Mar 12, 2014; 4

Non-profit

1

Inflammatory bowel disease (Crohn's, ulcerative colitis, IBS)

I: Plant-based cannabis

C: Placebo cigarettes (THC removed)

• Response rate

• QoL

• Remission rate

Only one study included

M

CADTH, 2014 [81]

Jan 1, 1982 to Aug 8 2014; 5

NR

4

Nausea and vomiting (non-chemotherapy-induced)

I: Synthetic cannabinoids

C: Metoclopramide

• Postoperative nausea and vomiting

• Patient rating of nausea and vomiting (VAS)

Only one study included

L

  1. CADTH Canadian Agency for Drugs and Technologies in Health, IBS irritable bowel syndrome, NR not reported, QoL quality of life, SBS study-by-study, VAS visual analog scale
  2. *A colon indicates that there were separate analyses for each comparator